![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/04/01/2855150/0/en/Disc-Reports-Topline-Results-from-Phase-2-AURORA-Study-of-Bitopertin-in-Patients-with-Erythropoietic-Protoporphyria-EPP.html
https://www.globenewswire.com//news-release/2023/12/12/2794346/0/en/Disc-Presents-Positive-Updated-Results-from-Phase-2-BEACON-Study-of-Bitopertin-and-Other-Programs-at-the-65th-American-Society-of-Hematology-ASH-Annual-Meeting.html
https://www.globenewswire.com/news-release/2023/07/27/2712248/0/en/Disc-Medicine-Announces-First-Patient-Enrolled-in-Phase-1-2-Clinical-Trial-of-Bitopertin-in-Diamond-Blackfan-Anemia-DBA.html
https://www.prnewswire.com/news-releases/disc-medicine-receives-fda-orphan-drug-designation-for-bitopertin-for-the-treatment-of-erythropoietic-protoporphyria-301710074.html
https://www.prnewswire.com/news-releases/disc-medicine-initiates-aurora-a-phase-2-clinical-study-of-bitopertin-in-adults-with-erythropoietic-protoporphyria-epp-301663323.html
https://www.biopharmadive.com/news/disc-medicine-gemini-reverse-merger-public/629389/
https://endpts.com/roche-schizophrenia-drug-that-failed-phiii-gets-a-new-life-in-rare-disorder-as-orbimed-leads-90m-for-startup/